Gunderson Dettmer represented venture firm Newpath Partners in the formation of its $350 million second fund, Newpath Partners II. With this fund, Newpath will continue its mission of partnering with leading scientific entrepreneurs to develop transformational therapies for complex diseases.

“Our team at Newpath Partners is guided by a simple ethos – do the right thing and good things will happen. This principle has attracted the continued support of our investors and bold ideas from leading scientists. Many of these ideas are now advancing through portfolio companies to drive solutions for the world’s greatest medical challenges,” said Thomas Cahill MD, PhD, founding partner of Newpath Partners.

The Gunderson deal team was led by Malcolm Nicholls and included Emily O’Brien, Blake Rowe and Gabrielle Paradis.

Newpath Partners